Try our corporate solution for free!

Sales share at risk of pharmaceuticals due to patent expiries U.S. 2022

Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries as of 2022

Exclusive Premium statistic

You need a Statista Account for unlimited access.

  • Full access to 1m statistics
  • Incl. source references
  • Available to download in PNG, PDF, XLS format
Statista Accounts

Access to this and all other statistics on 80,000 topics from

$468 USD / Year
$708 USD / Year

Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

May 2022

Region

United States

Survey time period

2022

Supplementary notes

Sales at risk is annual US sales in the year before patent expiry.

Citation formats
Statista Accounts: Access All Statistics. Starting from $468 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 USD $39 USD / Month *
in the first 12 months
Professional Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on " U.S. pharmaceutical industry "

Statistics on U.S. pharmaceutical industry

Contribution to global pharma

5

Overview

6

Companies

6

Research and development

7

Generics

5

Public view on pharma

6

Outlook

4

Further related statistics

21
Statista Accounts: Access All Statistics. Starting from $468 USD / Year
Learn more about how Statista can support your business.